Table 1 Baseline characteristics of patients recruited to the SIEGE trial.
Sequential arm (N = 71) | Concomitant arm (N = 75) | Total (N = 146) | |
|---|---|---|---|
Age | 63.45 (8.32) | 65.97 (8.16) | 64.75 (8.31) |
Sex | |||
Male | 43/71 (60.6%) | 40/75 (53.3%) | 83/146 (56.8%) |
Female | 28/71 (39.4%) | 35/75 (46.7%) | 63/146 (43.2%) |
Liver metastases present | |||
No | 11/71 (15.5%) | 13/75 (17.3%) | 24/146 (16.4%) |
Yes | 60/71 (84.5%) | 62/75 (82.7%) | 122/146 (83.6%) |
ECOG performance status | |||
0 | 30/70 (42.9%) | 33/75 (44%) | 63/145 (43.4%) |
1 | 39/70 (55.7%) | 38/75 (50.7%) | 77/145 (53.1%) |
2 | 1/70 (1.4%) | 4/75 (5.3%) | 5/145 (3.4%) |
CA19-9 (37 U/ml) | |||
≤37 U/ml | 10/69 (14.5%) | 10/70 (14.3%) | 20/139 (14.4%) |
>37 U/ml | 59/69 (85.5%) | 60/70 (85.7%) | 119/139 (85.6%) |
CA19-9 (200 U/ml) | |||
≤200 U/ml | 18/69 (26.1%) | 14/70 (20%) | 32/139 (23%) |
>200 U/ml | 51/69 (73.9%) | 56/70 (80%) | 107/139 (77%) |
CA19-9 (1000 U/ml) | |||
≤1000 U/ml | 31/69 (44.9%) | 22/70 (31.4%) | 53/139 (38.1%) |
>1000 U/ml | 38/69 (55.1%) | 48/70 (68.6%) | 86/139 (61.9%) |
Albumin | |||
<35 g/L | 18/71 (25.4%) | 16/75 (21.3%) | 34/146 (23.3%) |
≥35 g/L | 53/71 (74.6%) | 59/75 (78.7%) | 112/146 (76.7%) |
C-reactive protein | |||
≤10 mg/l | 32/70 (45.7%) | 37/72 (51.4%) | 69/142 (48.6%) |
>10 mg/l | 38/70 (54.3%) | 35/72 (48.6%) | 73/142 (51.4%) |
mGPS | |||
0 | 32/70 (45.7%) | 37/72 (51.4%) | 69/142 (48.6%) |
1 | 25/70 (35.7%) | 22/72 (30.6%) | 47/142 (33.1%) |
2 | 13/70 (18.6%) | 13/72 (18.1%) | 26/142 (18.3%) |
Neutrophils | |||
≤1*ULN | 48/71 (67.6%) | 59/75 (78.7%) | 107/146 (73.3%) |
>1*ULN | 23/71 (32.4%) | 16/75 (21.3%) | 39/146 (26.7%) |
mutKRAS ctDNA | |||
Detected | 6/12 (50%) | 8/11 (72.7%) | 14/23 (60.9%) |
Not detected | 6/12 (50%) | 3/11 (27.3%) | 9/23 (39.1%) |
